Bacterial Conjunctivitis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: BCT006 MIFTS: 42	Bacterial Conjunctivitis Categories: Eye diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Bacterial Conjunctivitis

MalaCards integrated aliases for Bacterial Conjunctivitis:

IMPROVED

Name: Bacterial Conjunctivitis ¹¹ ¹⁴ ¹⁶ ⁷¹

Conjunctivitis, Bacterial ⁴³

Purulent Conjunctivitis ¹¹

Classifications:

MalaCards categories:
Global: Infectious diseases Rare diseases
Anatomical: Neuronal diseases Eye diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the eye and adnexa

Disorders of conjunctiva

Conjunctivitis

Mucopurulent conjunctivitis

External Ids:

Disease Ontology ¹¹ DOID:9700

MeSH ⁴³ D003234

NCIt ⁴⁹ C53656

SNOMED-CT ⁶⁸ 193877001

ICD10 ³¹ H10.0

EFO ¹⁶ EFO_1000829

UMLS ⁷¹ C0009768

Sources

Summaries for Bacterial Conjunctivitis

MalaCards based summary: Bacterial Conjunctivitis, also known as conjunctivitis, bacterial, is related to conjunctivitis and haemophilus influenzae. An important gene associated with Bacterial Conjunctivitis is ITPKC (Inositol-Trisphosphate 3-Kinase C), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PAK Pathway. The drugs Moxifloxacin and Ethinylestradiol have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and neutrophil.

Sources

Related Diseases for Bacterial Conjunctivitis

Diseases in the Conjunctivitis family:

Acute Conjunctivitis	Chronic Conjunctivitis
Bacterial Conjunctivitis	Rare Conjunctivitis

Diseases related to Bacterial Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 953)

#	Related Disease	Score	Top Affiliating Genes
1	conjunctivitis	31.9	TNF IL6 IL10 CXCL8
2	haemophilus influenzae	31.0	TNF IL1B CXCL8
3	corneal ulcer	30.2	TNF IL6 IL1B
4	ophthalmia neonatorum	30.1	MTRR CEACAM3 CD4
5	trachoma	29.9	TNF IL6 IL10
6	eyelid disease	29.8	TNF IL6 CD4
7	keratitis, hereditary	29.7	TNF IL6 IL1B IL10 CXCL8 CD4
8	blepharitis	29.7	TNF IL6 IL1B CXCL8 CD4
9	chlamydia	29.6	TNF IL6 IL1B IL10 CXCL8 CRP
10	purpura	29.3	TNF IL6 IL1B IL10 CXCL8 CRP
11	endophthalmitis	29.1	TNF IL6 IL1B CXCL8 CRP CD4
12	chronic conjunctivitis	29.1	TNF IL6 IL1B IL10 CXCL8 CD4
13	meningitis	29.1	TNF IL6 IL1B IL10 CXCL8 CRP
14	allergic conjunctivitis	28.9	TNF IL6 IL1B IL10 CXCL8 CD4
15	iridocyclitis	28.9	TNF IL6 IL1B IL10 CXCL8 CRP
16	anterior uveitis	28.9	TNF IL6 IL1B IL10 CXCL8 CRP
17	otitis media	28.6	TNF IL6 IL1B IL10 GPT CXCL8
18	eye disease	28.2	TNF IL6 IL1B IL10 GPT CXCL8
19	skin disease	28.0	TNF IL6 IL1B IL10 GPT CXCL8
20	disease by infectious agent	27.9	TNF IL6 IL1B IL10 GPT CXCL8
21	acute conjunctivitis	10.5
22	noma	10.3	CXCL8 ALB
23	chronic duodenal ileus	10.3	CRP ALB
24	external pathological resorption	10.3	TNF IL6
25	ankylosing spondylitis 3	10.3	CRP ALB
26	renal tuberculosis	10.3	CRP ALB
27	anterior scleritis	10.3	TNF CRP
28	chronic intestinal vascular insufficiency	10.3	CRP ALB
29	acute vascular insufficiency of intestine	10.3	CRP ALB
30	peptic ulcer perforation	10.3	CRP ALB
31	posterior scleritis	10.3	TNF CRP
32	tuberculous peritonitis	10.3	CRP ALB
33	rheumatoid arthritis interstitial lung disease	10.3	TNF CRP
34	superior mesenteric artery syndrome	10.3	CRP ALB
35	gastric dilatation	10.3	CRP ALB
36	chronic orbital inflammation	10.3	TNF CRP
37	senile entropion	10.3	TNF CXCL8
38	null-cell leukemia	10.3	TNF IL6
39	erythema elevatum diutinum	10.3	CXCL8 CRP
40	interstitial keratitis	10.3	TNF CRP
41	ureterolithiasis	10.3	CRP ALB
42	chronic salpingitis	10.2	TNF CEACAM3
43	non-syndromic x-linked intellectual disability 96	10.2	IL1B ALB
44	periodontitis, chronic	10.2	IL6 IL1B
45	epididymo-orchitis	10.2	IL6 CRP
46	generalized atherosclerosis	10.2	IL6 CRP ALB
47	hemopericardium	10.2	NPPB CRP
48	osteosclerotic myeloma	10.2	IL6 IL1B
49	intracranial embolism	10.2	IL6 CRP ALB
50	alveolar periostitis	10.2	TNF IL6 CRP

Graphical network of the top 20 diseases related to Bacterial Conjunctivitis:

Sources

Symptoms & Phenotypes for Bacterial Conjunctivitis

Sources

Drugs & Therapeutics for Bacterial Conjunctivitis

Drugs for Bacterial Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Moxifloxacin

Approved, Investigational

Phase 4

186826-86-8, 354812-41-2, 151096-09-2

152946

Ethinylestradiol

Approved

Phase 4

57-63-6

5991

Estradiol

Approved, Investigational, Vet_approved

Phase 4

50-28-2

5757

Polyestradiol phosphate

Approved

Phase 4

28014-46-2

Norgestimate

Approved, Investigational

Phase 4

35189-28-7

6540478

Contraceptives, Oral, Combined

Phase 4

Contraceptives, Oral

Phase 4

Contraceptive Agents

Phase 4

Estradiol 3-benzoate

Phase 4

Estradiol 17 beta-cypionate

Phase 4

Norgestimate, ethinyl estradiol drug combination

Phase 4

Framycetin

Approved, Experimental, Vet_approved

Phase 3

1404-04-2, 3947-65-7, 119-04-0

413349 8378

Polymyxin B

Approved, Vet_approved

Phase 3

1405-20-5, 1404-26-8

4868

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3

50-02-2

3003 5743

Levofloxacin

Approved, Investigational

Phase 3

100986-85-4

149096

Ofloxacin

Approved

Phase 3

82419-36-1

4583

Iodine

Approved, Investigational

Phase 3

7553-56-2

807

Povidone-iodine

Approved

Phase 3

25655-41-8

Povidone K30

Approved, Experimental

Phase 3

9003-39-8

6917 131751496

Tobramycin

Approved, Investigational

Phase 3

32986-56-4

36294

Sorbitol

Approved, Investigational

Phase 3

69-65-8, 50-70-4

453 6251 5780

Pentetic acid

Approved

Phase 3

67-43-6

Sodium citrate

Approved, Investigational

Phase 3

68-04-2

23431961

Edetate calcium disodium anhydrous

Approved, Vet_approved

Phase 3

62-33-9, 60-00-4

6049

Calcium polycarbophil

Approved

Phase 3

126040-58-2

Vancomycin

Approved

Phase 3

1404-90-6

14969

Gatifloxacin

Approved, Investigational

Phase 3

112811-59-3

5379

Besifloxacin

Approved

Phase 3

141388-76-3

22743624 10178705

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Cadexomer iodine

Experimental

Phase 3

94820-09-4

Pazufloxacin

Investigational

Phase 3

127045-41-4

465466

Dexamethasone, neomycin, polymyxin B drug combination

Phase 3

Polymyxins

Phase 3

glucocorticoids

Phase 3

Hormones

Phase 3

Tobramycin, Dexamethasone Drug Combination

Phase 3

Hormone Antagonists

Phase 3

Anti-Inflammatory Agents

Phase 3

Cytochrome P-450 Enzyme Inhibitors

Phase 3

Citrate

Phase 3

Psyllium

Phase 3

Fluoroquinolones

Phase 3

Antitubercular Agents

Phase 3

Dipivefrin

Approved

Phase 2

52365-63-6

3105

Hyaluronic acid

Approved, Vet_approved

Phase 2

9004-61-9

53477741

Adjuvants, Immunologic

Phase 2

Protective Agents

Phase 2

Viscosupplements

Phase 2

Immunologic Factors

Phase 2

Interventional clinical trials:

(show all 35)

#	Name	Status	NCT ID	Phase	Drugs
1	Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment	Completed	NCT00798577	Phase 4	Vigamox Ophthalmic Solution;BSS placebo
2	Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora	Completed	NCT00312338	Phase 4	VIGAMOX
3	A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis	Completed	NCT00464438	Phase 4	gatifloxacin;moxifloxacin 0.5% eye drops
4	Randomized Clinical Trial Of Drug Topics Efficacy Maxinom® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Union Chemical) And Maxitrol® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Alcon) In Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis	Unknown status	NCT01227863	Phase 3	MAXINOM®;Maxitrol®
5	RANDOMIZED CLINICAL EVALUATION OF EFFECTIVENESS COMPARISON BETWEEN DRUGS OPHTHALMOLOGICAL TOBRACORT® (TOBRAMYCIN + DEXAMETHASONE - LAB. UNIÃO QUÍMICA)AND TOBRADEX® (TOBRAMYCIN + DEXAMETHASONE - LAB. ALCON) IN REDUCING THE SIGNS AND SYMPTOMS OF ACUTE BACTERIAL CONJUNCTIVITIS	Unknown status	NCT01227915	Phase 3	Tobracort;Tobradex
6	Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis	Completed	NCT00759148	Phase 3	Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%
7	An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients	Completed	NCT01573910	Phase 3	Moxifloxacin ophthalmic solution, 0.5%;Ofloxacin ophthalmic solution, 0.3%
8	A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis	Completed	NCT03004924	Phase 3	SHP640;PVP-I 0.6%;Placebo
9	A Single- Centre, Randomised Study Of The Clinical And Microbiological Efficacy Of Decreasing The Dosage Of Levofloxacin 0,5% Eye Drops As Compared To Standard Eye Drop Dosage In Patients With Bacterial Conjunctivitis	Completed	NCT00565123	Phase 2, Phase 3	0.5% levofloxacin eye drops
10	A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0 % AzaSite Compared to Vehicle in the Treatment of Bacterial Conjunctivitis	Completed	NCT00105534	Phase 3	AzaSite
11	A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0% AzaSite Compared to 0.3% Tobramycin Ophthalmic Solution in the Treatment of Bacterial Conjunctivitis	Completed	NCT00105469	Phase 3	AzaSite;Tobramycin
12	A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.	Completed	NCT00972777	Phase 2, Phase 3	Besifloxacin;Vehicle (Placebo)
13	Clinical Efficacy and Safety of T1225 1.5% Eye Drops (3-Day Treatment) Versus Tobramycin 0.3 % Eye Drops (7-Day Treatment) in the Treatment of Purulent Bacterial Conjunctivitis	Completed	NCT00357773	Phase 3	Azithromycin (T1225)
14	A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.	Completed	NCT00347932	Phase 3	ISV-403;Vehicle
15	Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.	Completed	NCT01155999	Phase 3	T1225;Tobramycin
16	A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis	Completed	NCT00518089	Phase 3	Gatifloxacin 0.5% eye drops;placebo eye drops
17	A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis	Completed	NCT00509873	Phase 3	Gatifloxacin 0.5% eye drops;placebo eye drops
18	A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis	Completed	NCT00348348	Phase 3	Besifloxacin;Moxifloxacin solution
19	An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in India	Completed	NCT00332293	Phase 3	Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%;Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
20	AL-15469A for the Treatment of Bacterial Conjunctivitis	Completed	NCT00331916	Phase 3	quinolone
21	A Randomized, Multicenter, Double-Masked, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Vancomycin Hydrochloride Ophthalmic Ointment 1.1% in Patients With Moderate to Severe Bacterial Conjunctivitis	Completed	NCT02432807	Phase 3	Vancomycin 1.1%;Placebo
22	A Study to Evaluate the Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Following Three Times Daily(TID) Dosing for 7 Days	Completed	NCT01175590	Phase 3	Besivance;Vehicle
23	A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis	Terminated	NCT01740388	Phase 3	Besifloxacin;Vehicle
24	Clinical Study of the Efficacy of the Ophthalmic Solution of Pazufloxacin 0.6% (PRO-157) for the Treatment of Acute Bacterial Conjunctivitis, Compared to the Ophthalmic Solution of Gatifloxacin 0.3%.	Terminated	NCT03696342	Phase 3	Pazufloxacin;Zymar
25	Evaluation of the Safety and Efficacy of Topical Besifloxacin Ophthalmic Suspension, 0.6% Compared With Gatifloxacin, 0.3% Ophthalmic Solution for the Treatment of Presumed Bacterial Conjunctivitis in Subjects From Birth to 31 Days of Age	Terminated	NCT01330355	Phase 3	Besivance;Gatifloxacin
26	Association of Azithromycin 1,5%/Loteprednol 0,5% Eye Drops Versus Individual Administration of Azithromycin 1,5% and Loteprednol 0,5% in the Treatment of Ocular Inflammation and Infection	Withdrawn	NCT01721694	Phase 3	azithromycin 1.5%/Loteprednol 0,5% + placebo;azithromycin 1.5% + Loteprednol 0,5% (separately)
27	A Randomized, Double Blind, Phase II Multicenter Trial to Evaluate the Safety and Efficacy of PRO-157 Ophthalmic Solution in Three Different Dosing Regimen Versus Moxifloxacin Versus Gatifloxacin in Patients With Bacterial Conjunctivitis.	Completed	NCT02980523	Phase 2	PRO-157;Vigamox;Zymar®;Lagricel Ofteno®
28	A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis	Completed	NCT00622908	Phase 2	ISV-403;Vehicle
29	A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis	Completed	NCT01877694	Phase 2	Auriclosene Solution 0.3%;Auriclosene Vehicle
30	Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis	Withdrawn	NCT01238783	Phase 2	AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension;AL-15469A 0.5%;AL-6515 0.3%;Vehicle
31	Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers	Unknown status	NCT03235141	Phase 1	azithromycin eye drops by essex;azithromycin eye drops
32	Systemic Pharmacokinetics of BOL-303224-A After Single and Multiple Instillations of BOL-303224-A in Subjects With Suspected Bacterial Conjunctivitis	Completed	NCT00407589	Phase 1	BOL-303224-A
33	Phase I Clinical Trial, to Evaluate the Safety and Tolerability of the Ophthalmic Solution PRO-174 Versus Sophixín Ofteno®, Elaborated by Laboratorios Sophia on the Ocular Surface of Ophthalmological and Clinically Healthy Subjects	Completed	NCT03519516	Phase 1	PRO-174;Sophixín Ofteno®
34	Study to Evaluate the Safety and Tolerability of Pro-143 Ophthalmic Solution in Healthy Volunteers.	Withdrawn	NCT03698045	Phase 1	PRO-143 Ophthalmic Solution
35	Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking Ophthalmologists	Completed	NCT03987178

Search NIH Clinical Center for Bacterial Conjunctivitis

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Ciprofloxacin

Loteprednol

loteprednol etabonate

Cochrane evidence based reviews: conjunctivitis, bacterial

Sources

Genetic Tests for Bacterial Conjunctivitis

Sources

Anatomical Context for Bacterial Conjunctivitis

Organs/tissues related to Bacterial Conjunctivitis:

MalaCards : Eye, Skin, Neutrophil, Kidney

Sources

Publications for Bacterial Conjunctivitis

Articles related to Bacterial Conjunctivitis:

(show top 50) (show all 595)

#	Title	Authors	PMID	Year
1	Universal newborn eye screening: a systematic review of the literature and review of international guidelines. ⁶²	Malik AN...Gilbert C	36269293	2022
2	Adult Eye Conditions: Common Eye Conditions. ⁶²	McGinley TC	35947131	2022
3	Five-year review of ocular Neisseria gonorrhoeae infections presenting to ophthalmology departments in Greater Glasgow & Clyde, Scotland. ⁶²	Butler L...Lockington D	34211138	2022
4	Indication-prescription study for the management of conjunctivitis in a Colombian population. ⁶²	Valladales-Restrepo LF...Machado-Alba JE	35776393	2022
5	Ciprofloxacin-Loaded Zein/Hyaluronic Acid Nanoparticles for Ocular Mucosa Delivery. ⁶²	Jacinto TA...Coutinho P	35893813	2022
6	A qualitative evaluation of pediatric conjunctivitis medical decision making and opportunities to improve care. ⁶²	Sebastian T...Frost HM	35421542	2022
7	Survey of state conjunctivitis policies for school-age students. ⁶²	Lee T...Kuo IC	35378302	2022
8	Successful use of tofacitinib in reactive arthritis refractory to conventional therapies - a case series. ⁶²	Maikap D...Padhan P	35024869	2022
9	Does This Patient With Acute Infectious Conjunctivitis Have a Bacterial Infection?: The Rational Clinical Examination Systematic Review. ⁶²	Johnson D...Simel D	35699701	2022
10	Cytological and microbiological evaluation of conjunctiva in camels with and without conjunctivitis. ⁶²	Shawaf T...Hussen J	35657141	2022
11	Spectrum and resistance in bacterial infections of the ocular surface in a German tertiary referral center 2009-2019. ⁶²	Roth M...Geerling G	35687174	2022
12	Multisystem inflammatory syndrome in children (MIS-С) associated with SARS-CoV-2 infection and severe abdominal syndrome. The Lviv "OHMATDYT" (Western Ukraine) experience. ⁶²	Lytvyn H...Pellicano R	35511674	2022
13	Safety of topical ophthalmic antibiotics in pregnant women with hordeola, chalazia, blepharitis, or bacterial conjunctivitis: propensity score analyses. ⁶²	Hashimoto Y...Aihara M	34035495	2022
14	Strabismus Surgery: A Retrospective Comparison of Different Postoperative Treatment Regimes to Prevent Infections. ⁶²	Felber D...Palmowski-Wolfe A	35472813	2022
15	Exploring community pharmacists' clinical decision-making using think aloud and protocol analysis. ⁶²	Mallinder A...Martini N	33985891	2022
16	In-situ tear fluid dissolving nanofibers enable prolonged viscosity-enhanced dual drug delivery to the eye. ⁶²	Rohde F...Windbergs M	35085733	2022
17	Differential Diagnostic Challenges in the COVID-19 Pandemic: Renal Abscess After SARS-CoV-2 Infection in a Young Adolescent. ⁶²	Martonosi AR...Szabo L	35279666	2022
18	Prevalence and Antimicrobial Resistance of Causative Agents to Ocular Infections. ⁶²	Manente R...Boccia G	35453215	2022
19	Clinical practice guidelines in multisystem inflammatory syndrome (MIS-C) related to COVID-19: a critical review and recommendations. ⁶²	Algarni AS...Alghamdi SH	34982402	2022
20	Incidence of Bacterial and Nonbacterial Conjunctivitis in Patients With Atopic Dermatitis Treated With Dupilumab: A US Multidatabase Cohort Study. ⁶²	Schneeweiss MC...Schneeweiss S	35170520	2022
21	Preparation of NLCs-Based Topical Erythromycin Gel: In Vitro Characterization and Antibacterial Assessment. ⁶²	Zafar A...Ghoneim MM	35200497	2022
22	Bilateral, chronic, bacterial conjunctivitis in giant fornix syndrome. ⁶²	Commiskey P...Mammen A	35027379	2022
23	Ofloxacin-Loaded Niosome-Laden Contact Lens: Improved Properties of Biomaterial for Ocular Drug Delivery. ⁶²	Liu J...Wang X	34851496	2021
24	Perspective on the clone library method for infectious diseases. ⁶²	Yatera K...Mukae H	34400128	2021
25	Conjunctival Sac Microbiome in Infectious Conjunctivitis. ⁶²	Mohamed YH...Yoshida LM	34683416	2021
26	Novel Chitosan-Coated Niosomal Formulation for Improved Management of Bacterial Conjunctivitis: A Highly Permeable and Efficient Ocular Nanocarrier for Azithromycin. ⁶²	Eid HM...Hegazy AM	33940026	2021
27	Purulent Conjunctivitis and Progressive Corneal Stromal Necrosis. ⁶²	Alsoudi AF...Seitzman GD	34081098	2021
28	Incomplete Kawasaki Disease as Presentation of COVID-19 Infection in an Infant: A Case Report. ⁶²	Raut S...Nandi M	32756980	2021
29	Antimicrobial Susceptibility Patterns and Resistance Trends of Staphylococcus aureus and Coagulase-Negative Staphylococci Strains Isolated from Ocular Infections. ⁶²	Petrillo F...Boccia G	34063711	2021
30	Infection After Endoscopic Dacryocystorhinostomy: Incidence and Implications. ⁶²	Jafari A...Metson R	32938219	2021
31	Pharmacists' and pharmacy technicians' scopes of practice in the management of minor ailments at community pharmacies in Indonesia: a cross-sectional study. ⁶²	Mizranita V...Hughes JD	34221196	2021
32	Influenza B infection and Kawasaki disease in an adolescent during the COVID-19 pandemic: a case report. ⁶²	Silveira JO...Renattini TSM	34231814	2021
33	Unraveling the Impact of Pneumococcal Conjugate Vaccines on Bacterial Conjunctivitis in Children. ⁶²	Howard LM...de St Maurice A	32140700	2021
34	A Prospective, Population-based Study to Determine the Incidence and Bacteriology of Bacterial Conjunctivitis in Children <2 Years of Age Following 7-Valent and 13-Valent Pneumococcal Conjugate Vaccine Sequential Implementation. ⁶²	Dagan R...Givon-Lavi N	32140705	2021
35	Antibacterial and COX-2 Inhibitory Tetrahydrobisbenzylisoquinoline Alkaloids from the Philippine Medicinal Plant Phaeanthus ophthalmicus. ⁶²	Magpantay HD...Macabeo APG	33804446	2021
36	Quinolone immediate hypersensitivity due to topical ophthalmic preparations: a case report and review of literature. ⁶²	Ajima S...Hashizume H	33112013	2021
37	Using Historical Data to Support Approval of Drug Products for Ophthalmia Neonatorum: Innovative Approach Toward Evidence-Based Medicine. ⁶²	Sun H...Chambers WA	33331874	2021
38	Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6. ⁶²	Blondeau JM...DeCory HH	34785887	2021
39	Expression levels of pro-inflammatory interleukin-8 and certain antimicrobial peptides in concurrent with bacterial conjunctivitis. ⁶²	Hosny AES...Khattab RA	34012880	2021
40	Cohort profile: Study on Zika virus infection in Brazil (ZIKABRA study). ⁶²	Calvet GA...ZIKABRA Study Team	33400705	2021
41	A progressive and severe rash - Answers. ⁶²	McCormack M...Ali M	35072390	2021
42	Predominant role of Haemophilus influenzae in the association of conjunctivitis, acute otitis media and acute bacterial paranasal sinusitis in children. ⁶²	Hu YL...Chen JM	33420151	2021
43	Antibacterial effects of antibiotics and cell-free preparations of probiotics against Staphylococcus aureus and Staphylococcus epidermidis associated with conjunctivitis. ⁶²	Mohamed S...Abdelhamid AG	33424249	2020
44	The in vitro efficacy of eye drops containing a bacteriophage solution specific for Staphylococcus spp. isolated from dogs with bacterial conjunctivitis. ⁶²	Urban-Chmiel R...Dec M	33319700	2020
45	Reply to Comment on: A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis. ⁶²	Ta CN...Segal B	32826036	2020
46	Comment on: A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis. ⁶²	Kanclerz P...Myers WG	32826035	2020
47	COVID-19 and Telehealth: Prevention of Exposure in a Medically Complex Patient With a Mild Presentation. ⁶²	Chavis A...Hasan R	32593563	2020
48	Self-reported confidence with ocular examination and management of eye diseases by general medical practitioners. ⁶²	Onyiaorah AA...N Nwosu SN	32913165	2020
49	Parinaud's Oculoglandular Syndrome: A Case in an Adult with Flea-Borne Typhus and a Review. ⁶²	Dixon MK...Anstead GM	32751142	2020
50	Conjunctivitis: A Systematic Review. ⁶²	Azari AA...Arabi A	32864068	2020

Sources

Genes for Bacterial Conjunctivitis

Genes related to Bacterial Conjunctivitis (0 elite genes):

(show all 16)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ITPKC	Inositol-Trisphosphate 3-Kinase C	Protein Coding	5.88	DISEASES inferred ¹⁴
2	CRP	C-Reactive Protein	Protein Coding	5.83	DISEASES inferred ¹⁴
3	CNIH1	Cornichon Family AMPA Receptor Auxiliary Protein 1	Protein Coding	5.19	DISEASES inferred ¹⁴
4	SKIC3	SKI3 Subunit Of Superkiller Complex	Protein Coding	4.95	DISEASES inferred ¹⁴
5	IL6	Interleukin 6	Protein Coding	4.92	DISEASES inferred ¹⁴
6	ALB	Albumin	Protein Coding	4.84	DISEASES inferred ¹⁴
7	TNF	Tumor Necrosis Factor	Protein Coding	4.84	DISEASES inferred ¹⁴
8	CEACAM3	CEA Cell Adhesion Molecule 3	Protein Coding	4.81	DISEASES inferred ¹⁴
9	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	4.73	DISEASES inferred ¹⁴
10	NPPB	Natriuretic Peptide B	Protein Coding	4.72	DISEASES inferred ¹⁴
11	IL1B	Interleukin 1 Beta	Protein Coding	4.67	DISEASES inferred ¹⁴
12	FAM167A	Family With Sequence Similarity 167 Member A	Protein Coding	4.61	DISEASES inferred ¹⁴
13	IL10	Interleukin 10	Protein Coding	4.59	DISEASES inferred ¹⁴
14	CD4	CD4 Molecule	Protein Coding	4.51	DISEASES inferred ¹⁴
15	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	4.39	DISEASES inferred ¹⁴
16	MTRR	5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase	Protein Coding	4.36	DISEASES inferred ¹⁴

Sources

Variations for Bacterial Conjunctivitis

Sources

Expression for Bacterial Conjunctivitis

Search GEO for disease gene expression data for Bacterial Conjunctivitis.

Sources

Pathways for Bacterial Conjunctivitis

Pathways related to Bacterial Conjunctivitis according to GeneCards Suite gene sharing:

(show all 45)

#	Super pathways	Score	Top Affiliating Genes
1	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.25	TNF IL6 IL1B IL10 CXCL8 CD4
2	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.23	TNF IL6 IL1B IL10 CXCL8 CD4
3	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.58	TNF IL6 IL1B IL10 CXCL8
4	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.55	TNF IL6 IL1B IL10 CD4
5	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.46	TNF IL6 IL1B CXCL8
6	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.36	CXCL8 IL1B IL6 TNF
7	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.27	TNF IL6 IL1B CXCL8
8	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	12.11	TNF IL6 IL1B IL10 CXCL8
9	Neuroinflammation and glutamatergic signaling ⁷⁴	12.08	TNF IL6 IL1B IL10
10	Spinal cord injury ⁷⁴	11.97	TNF IL6 IL1B CXCL8
11	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.96	TNF IL6 IL10 CEACAM3 CD4
12	Senescence and autophagy in cancer ⁷⁴	11.89	IL6 IL1B CXCL8
13	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.89	TNF IL6 IL1B IL10 CXCL8
14	Allograft rejection ⁷⁴	11.87	CXCL8 IL10 IL1B TNF
15	CCL18 signaling pathway ⁷⁴	11.84	IL6 IL10 CXCL8
16	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.82	CD4 IL1B IL6
17	Innate Lymphoid Cells Differentiation ⁶⁵	11.8	TNF IL1B IL10 CD4
18	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.77	IL6 CXCL8 CRP CD4
19	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	11.77	TNF IL6 IL1B IL10 CD4
20	Burn wound healing ⁷⁴	11.75	TNF IL6 IL1B CXCL8
21	Acute viral myocarditis ⁷⁴	11.72	IL6 IL10 CD4
22	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.72	TNF IL6 IL10 CRP
23	Th17 cell differentiation pathway ⁷⁴	11.67	IL6 IL1B CD4
24	AP-1 transcription factor network ⁶¹	11.67	IL6 IL10 CXCL8
25	Lung fibrosis ⁷⁴	11.66	CXCL8 IL1B IL6 TNF
26	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.65	CXCL8 IL1B IL6 TNF
27	miRNAs involvement in the immune response in sepsis ⁷⁴	11.63	TNF IL6 IL10 CXCL8
28	IL 10 signaling pathway ⁶⁷	11.62	TNF IL6 IL1B IL10
29	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.59	TNF IL6 IL10
30	SARS-CoV-2 innate immunity evasion and cell-specific immune response ⁷⁴	11.53	TNF IL10 CXCL8
31	"Non-genomic actions of 1,25 dihydroxyvitamin D3" ⁷⁴	11.52	TNF IL6 CXCL8
32	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.52	TNF IL6 IL1B IL10 CD4
33	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.46	IL1B IL6 TNF
34	IL-10 Pathway ⁶⁴	11.32	IL10 IL1B IL6 TNF
35	Development and heterogeneity of the ILC family ⁷⁴	11.3	TNF IL6 IL1B
36	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.18	TNF IL6 IL1B CXCL8
37	LDL- influence on CD14 and TLR4 ⁷⁴	11.1	IL6 IL1B IL10
38	Prostaglandin signaling ⁷⁴	11.07	CXCL8 IL1B IL6 TNF
39	Interleukin-10 signaling ⁶⁶	11.03	TNF IL6 IL1B IL10 CXCL8
40	G-protein signaling_Rap2B regulation pathway ²²	10.97	TNF IL6 IL1B IL10 CXCL8
41	IL-9 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	10.77	IL6 IL1B
42	Overview of nanoparticle effects ⁷⁴	10.74	TNF IL6 CXCL8 CRP
43	COVID-19 adverse outcome pathway ⁷⁴	10.68	IL6 CXCL8
44	Cytokines and inflammatory response ⁷⁴	10.48	TNF IL6 IL1B IL10 CD4
45	Cells and molecules involved in local acute inflammatory response ⁷⁴ Show member pathways IL8-mediated signaling events ⁶¹	10.31	TNF IL6 CXCL8

Sources

GO Terms for Bacterial Conjunctivitis

Cellular components related to Bacterial Conjunctivitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.55	TNF NPPB IL6 IL1B IL10 GPT

Biological processes related to Bacterial Conjunctivitis according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	defense response to Gram-positive bacterium	GO:0050830	10.13	TNF IL6 IL1B CRP
2	positive regulation of DNA-binding transcription factor activity	GO:0051091	10.11	TNF IL6 IL1B IL10
3	regulation of insulin secretion	GO:0050796	10.06	TNF IL6 IL1B
4	response to activity	GO:0014823	10.05	TNF IL6 IL10
5	cellular response to lipopolysaccharide	GO:0071222	10.02	TNF IL6 IL1B IL10 CXCL8
6	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	10.01	IL10 IL6 TNF
7	positive regulation of chemokine production	GO:0032722	9.97	TNF IL6 IL1B
8	immune response	GO:0006955	9.96	TNF IL6 IL1B IL10 CXCL8 CNIH1
9	liver regeneration	GO:0097421	9.95	IL10 IL6 TNF
10	negative regulation of neurogenesis	GO:0050768	9.93	TNF IL6 IL1B
11	negative regulation of cytokine production involved in immune response	GO:0002719	9.89	TNF IL10
12	positive regulation of glial cell proliferation	GO:0060252	9.88	TNF IL6 IL1B
13	positive regulation of fever generation	GO:0031622	9.86	TNF IL1B
14	sequestering of triglyceride	GO:0030730	9.85	TNF IL1B
15	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.8	TNF IL1B
16	positive regulation of heterotypic cell-cell adhesion	GO:0034116	9.8	IL10 IL1B TNF
17	chronic inflammatory response to antigenic stimulus	GO:0002439	9.73	TNF IL10
18	positive regulation of neuroinflammatory response	GO:0150078	9.63	TNF IL6 IL1B
19	negative regulation of lipid storage	GO:0010888	9.43	TNF IL6 CRP
20	vascular endothelial growth factor production	GO:0010573	9.1	TNF IL6 IL1B